Pluvicto's Biggest Expansion Yet: What the mHSPC Approval Means for Radioligand Therapy

On July 31, 2026, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use in combination with an androgen receptor pathway inhibitor in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The approval came one month ahead of the FDA's goal date, and it carries a significance that extends well beyond the regulatory calendar. Pluvicto can now be deployed across all stages of PSMA-positive metastatic prostate cancer, nearly doubling the number of patients eligible for the therapy. For Novartis, it is the most consequential label expansion since the drug's original approval in 2022. For the broader field of radioligand therapy, it is a validation that the class is moving earlier in the treatment journey, and that the logic of targeted radiation is proving durable across disease contexts.

What the PSMAddition Trial Actually Showed

The approval rests on data from the Phase 3 PSMAddition trial, which enrolled 1,144 patients with PSMA-positive metastatic hormone-sensitive prostate cancer and randomized them 1:1 to receive Pluvicto plus standard of care (androgen deprivation therapy and an ARPI) or standard of care alone. At the primary analysis, Pluvicto reduced the risk of radiographic progression or death by 28% (HR 0.72; 95% CI: 0.58 to 0.90). A subsequent updated analysis pushed that figure to a 33% reduction (HR 0.67; 95% CI: 0.55 to 0.82), with a positive overall survival trend favoring the Pluvicto arm (HR 0.80; 95% CI: 0.63 to 1.01). Complete responses were achieved in 57.1% of patients on the combination versus 42.3% on standard of care alone.

The OS confidence interval crossing 1.0 is the live question in this dataset. The data have not yet matured to a final overall survival read, and that final analysis will be the decisive moment for oncologists and payers weighing treatment intensification against a therapy that carries a grade 3 or higher adverse event rate of 50.7% versus 43.0% for standard of care alone. Dry mouth, fatigue, nausea, hot flush, and anemia dominated the all-grade toxicity profile, consistent with findings from the earlier VISION and PSMAfore trials. The FDA approved the drug on the strength of the radiographic progression-free survival data, but the commercial and clinical case for Pluvicto in this setting will ultimately be made or broken by the OS readout.

The Strategic Scope of the Expansion

Metastatic hormone-sensitive prostate cancer is a substantially larger population than the castration-resistant settings where Pluvicto previously operated. More than 186,000 men are diagnosed with mHSPC globally each year, and the PSMA biomarker is present in more than 80% of prostate cancer patients. Novartis has stated that the mHSPC indication nearly doubles the eligible patient pool, and the company has pinned $5 billion in peak sales expectations on Pluvicto. That target, which once seemed ambitious, now looks considerably more achievable. The drug is the only PSMA-targeted agent approved across the full spectrum of metastatic prostate cancer, a position that no competitor currently occupies.

The approval also arrives at a moment when Novartis has invested heavily in the manufacturing and logistics infrastructure required to deliver radioligand therapies at scale. The company operates five US manufacturing sites and has stated a delivery window of five days to treatment centers. That operational capability matters in a therapy class where the radioactive payload has a finite shelf life and where treatment site certification requirements create real barriers to access. Novartis has spent years building the end-to-end ecosystem that makes Pluvicto commercially viable, and the mHSPC approval gives that infrastructure a substantially larger patient base to serve.

What This Means for the Radioligand Therapy Class

The broader significance of this approval is what it signals about the trajectory of radioligand therapy as a modality. Pluvicto's original approval in 2022 was for heavily pretreated patients who had already received both an ARPI and taxane-based chemotherapy. The March 2025 expansion moved it earlier, into patients who had received an ARPI but not yet chemotherapy. The July 2026 approval moves it earlier still, into patients who are hormone-sensitive and have not yet progressed to castration resistance. Each step up the treatment chain represents a larger patient population and a longer potential treatment horizon.

This pattern of sequential label expansion is not unique to Pluvicto, but the speed and consistency with which it has occurred is notable. The underlying biology is holding up across disease contexts, and the PSMA biomarker is proving to be a reliable patient selection tool. The field is now watching whether Novartis can extend the same logic into oligometastatic prostate cancer, where the PSMA-DC trial is currently enrolling. If radioligand therapy can demonstrate benefit in earlier, lower-burden disease, the implications for the class extend well beyond prostate cancer.

The Questions That Remain

The mHSPC landscape already includes effective oral ARPIs, and the treatment intensification argument for adding Pluvicto to an already active doublet will face scrutiny from payers and guideline committees. Roughly a third of men with mHSPC never achieve undetectable PSA on standard doublet therapy, and half progress to castration-resistant disease within 20 months. That compression of the window for durable disease control is precisely the clinical problem Pluvicto is positioned to address. But the final overall survival data from PSMAddition will determine whether the drug earns a place in first-line treatment algorithms or remains a precision option for select patients who fail to respond adequately to standard approaches.

For Novartis, the approval removes a significant uncertainty from the Pluvicto commercial story and provides a clear path toward the $5 billion peak sales target. For patients with metastatic prostate cancer, it opens a targeted treatment option at a stage of disease where the window for intervention is still wide. And for the radioligand therapy field, it is the clearest evidence yet that targeted radiation is not a last resort. It is becoming a first-line consideration.